Hypochondroplasia
RecruitingLong‑Term Safety and Efficacy of Infigratinib in Children with Hypochondroplasia
- Disease:Hypochondroplasia
- Substances:Infigratinib
Norway- Participants:0–17 years
- Substances:Infigratinib
- Sponsor:Qed Therapeutics Inc.
Rare diseases
Investigational molecules
Locations

1800 Owens Street Ste C1200, 94158-2584, United States
Clinical research in achondroplasia centers on pediatric growth disorders, with attention to long-term safety, tolerability, and changes in standing height Z-score. The sponsor’s trials include children across multiple age ranges, reflecting a sustained interest in skeletal dysplasia and growth-related outcomes.
Research activity in this area also includes younger children and infants, indicating focus on early-life management of genetic short stature.
Qed Therapeutics Inc. runs clinical trials in conditions such as Osteochondrodysplasia, Hypochondroplasia, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Norway
Norway
France
France
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.